Analysis of warning letters issued by the US Food and Drug Administration to clinical investigators, institutional review boards and sponsors: A retrospective study

Journal of Medical Ethics

Volumn 41, Issue 5, 2015, Pages 398-403

  Shetty, Yashashri C ^a   Saiyed, Aafreen A ^a  

^a KEM HOSPITAL   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ETHICS; FINANCIAL MANAGEMENT; FOOD AND DRUG ADMINISTRATION; HUMAN; PERSONNEL; PROFESSIONAL STANDARD; RETROSPECTIVE STUDY; STANDARDS; UNITED STATES; WRITING;

CORRESPONDENCE AS TOPIC; ETHICS COMMITTEES, RESEARCH; HUMANS; RESEARCH PERSONNEL; RESEARCH SUPPORT AS TOPIC; RETROSPECTIVE STUDIES; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84929515125     PISSN: 03066800     EISSN: 14734257     Source Type: Journal    
DOI: 10.1136/medethics-2013-101829     Document Type: Article

References (20)

1. Wolf LE, Lo B. What about the ethics? West J Med 1999;171:365-6.
2. Alliance for Human Research Protection. Conflicts of Interests in Clinical Trials. 5-7 May, 2002. http://www.ahrp.org/cms/content/view/230/144/ (accessed 12 Feb 2013).
3. Levine R. Ethics and regulations of clinical research. 2nd edn. Munich: Urban and Schwarzenberg, 1986.
4. Wolf LE, Ferrara Walden J, Lo B. Human subjects issues and IRB review in practice based research. Ann Fam Med 2005;3(Supp 1):S30-37.
5. US Food and Drug Administration. Inspections, Compliance, Enforcement, and Criminal Investigations: Warning Letter Procedures. Aug 2012. http://www.fda.gov/ ICECI/ComplianceManuals/RegulatoryProceduresManual/ucm176870.htm (accessed 12 Feb 2013).
6. Raub WF. Efforts to Protect Human Research Subjects. US Food and Drug Administration. Aug 2009. http://www.fda.gov/newsevents/testimony/ucm114943. htm (accessed 18 May 2014).
7. US Food and Drug Administration. Information Sheet Guidance for IRBs, Clinical Investigators, and Sponsors. Jan 2006. http://www.fda.gov/downloads/ RegulatoryInformation/Guidances/UCM126555.pdf (accessed 28 Apr 2013).
8. ICH Harmonised Tripartite Guideline. Guideline For Good Clinical Practice E6(R1). Jun 1996:5. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/ Efficacy/E6_R1/Step4/E6_R1__Guideline.pdf (accessed 23 Jan 2013).
9. US Food and Drug Administration. Information Sheet Guidance For IRBs, Clinical Investigators, and Sponsors. Jun 2010. http://www.fda.gov/downloads/ RegulatoryInformation/Guidances/UCM126553.pdf (accessed 8 Mar 2013).
10. US Food and Drug Administration. Guidance for Industry and Clinical Investigators: The Use of Clinical Holds Following Clinical Investigator Misconduct. Sept 2004. http://www.fda.gov/downloads/RegulatoryInformation/Guidances/UCM126997.pdf (accessed 15 Apr 2013).
11. US Food and Drug Administration. Guidance for Clinical Trial Sponsors: Establishment and Operation of Clinical Trial Data Monitoring Committees. Mar 2006. http://www.fda.gov/downloads/Regulatoryinformation/Guidances/ ucm127073.pdf (accessed 23 Jan 2013).
12. Shetty YC, Jadhav KS, Saiyed AA, et al. Are institutional review boards prepared for active continuing review? Perspect Clin Res. 2014;5(1):11-5.
13. Parker C. The Sponsor: Responsibilities in Medical Device Clinical Trials. US Food and Drug Administration. Feb 2009. http://www.fda.gov/downloads/Training/ CDRHLearn/UCM176457.pdf (accessed 28 Jan 2013).
14. US Food and Drug Administration. Science&Research: Compliance&Enforcement. Sep 2013. http://www.fda.gov/ScienceResearch/SpecialTopics/RunningClinicalTrials/ ComplianceEnforcement/default.htm (accessed 28 Jan 2013).
15. US Food and Drug Administration. Inspections, Compliance, Enforcement, and Criminal Investigations: Warning Letters. Aug 2012. http://www.fda.gov/ICECI/ ComplianceManuals/RegulatoryProceduresManual/ucm176870.htm (accessed 19 Mar 2013).
16. Bramstedt AK. A study of warning letters issued to clinical investigators by the United States Food and Drug Administration. Clin Invest Med 2004;27(3):129-34.
17. Bramstedt AK, Kassimatis K. A study of warning letters issued to institutional review boards by the United States Food and Drug Administration. Clin Invest Med 2004;27(6):316-23.
18. Gogtay NJ, Doshi BM, Kannan S, et al. A study of warning letters issued to clinical investigators and institutional review boards by the United States Food and Drug Administration. Indian J Med Ethics 2011;8(4):211-14.
19. US Food and Drug Administration. Inspections, Compliance, Enforcement, and Criminal Investigations: Warning Letters Index. May 2014. http://www. fda.gov/ICECI/EnforcementActions/WarningLetters/default.htm (accessed 16 Feb 2013).
20. Warner TD, Gluck JP. What do we really know about conflicts of interest in biomedical research? Psychopharmacology (Berl) 2003;171(1):36-46.